Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
November 14, 2024 16:01 ET
|
Celcuity Inc.
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash...
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
November 12, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
November 07, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
August 14, 2024 16:01 ET
|
Celcuity Inc.
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast...
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
August 07, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity To Participate in Jefferies Global Healthcare Conference
June 03, 2024 16:01 ET
|
Celcuity Inc.
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Announces Pricing of Underwritten Common Stock Offering
May 30, 2024 07:36 ET
|
Celcuity Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
May 30, 2024 07:00 ET
|
Celcuity Inc.
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
May 15, 2024 16:01 ET
|
Celcuity Inc.
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating...
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
May 08, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...